Therapeutic targeting of specific neuronal subsets within these circuits, rather than multiple hormone receptors distributed throughout the body, offers a far more specific approach to the treatment of obesity-associated metabolic disease. The gene discussed is NR4A1; the disease is obesity due to melanocortin 4 receptor deficiency.